Welcome to LookChem.com Sign In|Join Free

CAS

  • or
lygtf is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1632051-40-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1632051-40-1 Structure
  • Basic information

    1. Product Name: lygtf
    2. Synonyms: lygtf;SAGE-217;217
    3. CAS NO:1632051-40-1
    4. Molecular Formula: C25H35N3O2
    5. Molecular Weight: 409.5643
    6. EINECS: -0
    7. Product Categories: N/A
    8. Mol File: 1632051-40-1.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 574.3±30.0 °C(Predicted)
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.32±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 15.17±0.60(Predicted)
    10. CAS DataBase Reference: lygtf(CAS DataBase Reference)
    11. NIST Chemistry Reference: lygtf(1632051-40-1)
    12. EPA Substance Registry System: lygtf(1632051-40-1)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1632051-40-1(Hazardous Substances Data)

1632051-40-1 Usage

Uses

Zuranolone is a potent GABAA receptor agonist.

Check Digit Verification of cas no

The CAS Registry Mumber 1632051-40-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,3,2,0,5 and 1 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1632051-40:
(9*1)+(8*6)+(7*3)+(6*2)+(5*0)+(4*5)+(3*1)+(2*4)+(1*0)=121
121 % 10 = 1
So 1632051-40-1 is a valid CAS Registry Number.

1632051-40-1Downstream Products

1632051-40-1Relevant articles and documents

FORMULATIONS OF 19-NOR C3,3- DISUBSTITUTED C21-N-PYRAZOLYL STEROID AND METHODS OF USE THEREOF

-

Paragraph 00488, (2022/02/05)

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and pharmaceutical compositions thereof. Also disclosed herein are methods of making the pharmaceutical compositions of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor

Martinez Botella, Gabriel,Salituro, Francesco G.,Harrison, Boyd L.,Beresis, Richard T.,Bai, Zhu,Blanco, Maria-Jesus,Belfort, Gabriel M.,Dai, Jing,Loya, Carlos M.,Ackley, Michael A.,Althaus, Alison L.,Grossman, Scott J.,Hoffmann, Ethan,Doherty, James J.,Robichaud, Albert J.

, p. 7810 - 7819 (2017/10/06)

Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABAA receptors. Herein, we report new SAR insights in a series of 5β-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties. Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).

19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF

-

, (2014/11/11)

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1632051-40-1